PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1916506
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1916506
Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
Growth Factors of vaccines Market
The global vaccines market size was valued at USD 88.92 billion in 2025 and is projected to grow to USD 95.68 billion in 2026, reaching USD 211.58 billion by 2034, registering a CAGR of 10.43% during the forecast period (2026-2034). North America dominated the global vaccines market with a 45.42% market share in 2025, supported by strong immunization coverage, favorable reimbursement frameworks, and the presence of leading vaccine manufacturers.
Vaccines remain one of the most cost-effective public health tools for preventing infectious diseases and reducing long-term healthcare expenditure. Rising disease prevalence, expanding immunization schedules, and increasing awareness programs are strengthening global vaccine adoption.
Market Drivers
The rising incidence of infectious diseases is a major factor driving vaccine demand. According to the U.S. Centers for Disease Control and Prevention, 422 meningococcal disease cases were reported in the U.S. in 2023, the highest since 2014. Growing disease outbreaks increase government spending on immunization and expand procurement of routine and booster doses.
Large-scale public health programs are further supporting market growth. In November 2024, India's Ministry of Health and Family Welfare announced annual observance of World Immunization Day on November 10, strengthening awareness under the Universal Immunization Programme (UIP), one of the world's largest public health initiatives.
Strong manufacturer pipelines, global supply contracts, and improved delivery networks continue to increase vaccine coverage across pediatric and adult populations.
Market Restraints
Despite strong demand, high development and production costs restrict market expansion, particularly in low-income countries. According to the U.S. Assistant Secretary for Planning and Evaluation, the average preventive vaccine development cost is USD 132.7 million, excluding manufacturing facilities and distribution infrastructure.
Complex regulatory requirements, long clinical development timelines, and strict quality controls increase pricing pressures. These factors reduce affordability in developing economies and slow product launches in smaller regional markets.
Market Opportunities
Expanding R&D investment is creating strong opportunities for pipeline expansion across viral and bacterial disease segments. Growing focus on hepatitis, dengue, Ebola, pneumococcal disease, and shingles is accelerating clinical development activity.
The COVID-19 pandemic demonstrated rapid vaccine development feasibility using advanced platforms and global funding coordination. Companies are now leveraging mRNA, viral vector, and recombinant technologies to shorten development cycles.
In June 2024, Dynavax Technologies initiated Phase 1/2 trials for Z-1018, an investigational shingles vaccine candidate, reflecting increasing private-sector investments in preventive medicine.
Market Challenges
Stringent regulatory guidelines across regions increase compliance complexity and delay approvals. Additionally, vaccines require strict cold-chain logistics, making transportation and storage difficult in remote and underdeveloped regions.
Supply chain disruptions, refrigeration limitations, and infrastructure gaps hinder last-mile delivery, affecting coverage in emerging markets and slowing national immunization rollouts.
Vaccines Market Trends
Manufacturers are increasingly shifting from traditional vials to prefilled syringe (PFS) formats, which reduce contamination risks, dosing errors, and product wastage. PFS also improves vaccination efficiency during mass immunization programs.
In September 2022, BD launched next-generation glass prefillable syringes to meet evolving vaccine manufacturing needs. Regulatory approvals for PFS-based vaccines are further accelerating adoption.
Segmentation Analysis
By Type
The recombinant/conjugate/subunit vaccine segment dominated the market with 46.88% share in 2026, driven by strong safety profiles, stable immune responses, and scalable production processes. Bavarian Nordic's VIMKUNYA recombinant chikungunya vaccine received European approval in February 2025.
The inactivated segment held the second-largest share, supported by rising demand for rabies, influenza, hepatitis A, and typhoid vaccines. Sanofi's Verorab rabies vaccine launch in the U.K. in April 2024 supported segment growth.
The mRNA segment is expected to grow at the fastest rate due to expanding indications beyond COVID-19. In August 2024, Pfizer and BioNTech reported Phase 3 data for combined influenza-COVID mRNA vaccine candidates.
By Route of Administration
Parenteral vaccines dominated the market with 85.18% share in 2026, supported by widespread intramuscular and subcutaneous formulations. Regulatory approvals for injectable vaccines continue to rise.
Oral vaccines show slower adoption due to formulation challenges but maintain growth in cholera and polio prevention programs.
By Disease Indication
Viral diseases accounted for 66.01% market share in 2026, driven by influenza, HPV, RSV, hepatitis, and shingles vaccines. Government awareness campaigns and routine booster programs continue to expand viral vaccine uptake.
Bacterial vaccines are expected to grow at higher CAGR due to antibiotic resistance and rising neonatal immunization programs. In March 2025, Merck received EU approval for CAPVAXIVE pneumococcal vaccine.
By Age Group
The pediatric segment dominated with 52.74% share in 2026, supported by birth rates and mandatory childhood vaccination schedules. Government-funded immunization programs remain major contributors.
The adult segment is growing due to increased RSV, HPV, and Mpox vaccination programs targeting older populations.
By Distribution Channel
Government suppliers dominated procurement through UNICEF, PAHO, and national programs. Hospital and retail pharmacies accounted for 48.1% share in 2025, supported by improved accessibility and consumer convenience.
Regional Outlook
North America generated USD 40.39 billion in 2025 and USD 43.82 billion in 2026, supported by public funding, CDC recommendations, and manufacturer presence. The U.S. alone reached USD 36.92 billion in 2026.
Asia Pacific reached USD 22.14 billion in 2025, driven by rising birth rates, government programs, and expanding manufacturing capacity. China reached USD 2.68 billion in 2026, while India stood at USD 2.46 billion in 2025.
Europe generated USD 19.07 billion in 2025, supported by centralized healthcare systems and increasing regulatory approvals, with Germany at USD 5.11 billion and France at USD 4.36 billion.
Latin America reached USD 5.95 billion in 2025, while GCC countries accounted for USD 0.53 billion in 2025, supported by expanding national immunization budgets.
Competitive Landscape
Major players including GSK, Pfizer, Sanofi, Merck, Moderna, CSL, AstraZeneca, and Bavarian Nordic dominate through strong product portfolios and continuous R&D investment. Strategic acquisitions, regulatory approvals, and pipeline expansion remain core growth strategies across the vaccines industry.
Conclusion
The global vaccines market is on a strong growth trajectory, expanding from USD 88.92 billion in 2025 to USD 95.68 billion in 2026, and projected to reach USD 211.58 billion by 2034, driven by rising infectious disease burden, expanding national immunization programs, and continuous innovation in vaccine technologies. North America remains the leading region with a 45.42% share in 2025, supported by strong public health funding and rapid regulatory approvals, while Asia Pacific is emerging as a high-growth region due to increasing birth rates and government vaccination initiatives. Segment-wise, recombinant/conjugate/subunit vaccines (46.88% share in 2026) and parenteral administration (85.18% share in 2026) dominate due to proven efficacy and widespread clinical adoption, while viral disease vaccines account for the majority of demand with 66.01% share in 2026. Although high development costs, regulatory complexity, and cold-chain logistics remain key challenges, rising R&D investments, expansion of mRNA platforms, and the shift toward prefilled syringes are strengthening production efficiency and distribution reliability. Overall, vaccines continue to remain a cornerstone of global preventive healthcare, with sustained demand across pediatric and adult populations supporting long-term market expansion.
Segmentation By Type
- Live Attenuated
- Inactivated
- Recombinant/Conjugate/Subunit
- mRNA Vaccine
- Viral Vectors Vaccines
- Toxoid
- Others
By Route of Administration
- Parenteral
- Oral
By Disease Indication
- Viral Diseases
- Hepatitis A
- Hepatitis B
- Polio
- RSV
- Influenza
- HPV
- Measles/Mumps/Rubella
- Rotavirus
- Shingles (Herpes Zoster)
- Others
- Bacterial Diseases
- Pneumococcal Diseases
- Diphtheria/Tetanus/Pertussis
- Meningococcal Diseases
- Others
- Others
By Age Group
- Pediatric
- Adults
By Distribution Channel
- Hospital & Retail Pharmacies
- Government Suppliers
- Others
By Region
- North America (By Type, Route of Administration, Disease Indication, Age Group, Distribution Channel, and Country)
- U.S. (By Type)
- Canada (By Type)
- Europe (By Type, Route of Administration, Disease Indication, Age Group, Distribution Channel, and Country/Sub-region)
- U.K. (By Type)
- Germany (By Type)
- France (By Type)
- Italy (By Type)
- Spain (By Type)
- Scandinavia (By Type)
- Rest of Europe (By Type)
- Asia Pacific (By Type, Route of Administration, Disease Indication, Age Group, Distribution Channel, and Country/Sub-region)
- China (By Type)
- Japan (By Type)
- India (By Type)
- Australia (By Type)
- Southeast Asia (By Type)
- Rest of Asia Pacific (By Type)
- Latin America (By Type, Route of Administration, Disease Indication, Age Group, Distribution Channel, and Country/Sub-region)
- Brazil (By Type)
- Mexico (By Type)
- Rest of Latin America (By Type)
- Middle East & Africa (By Type, Route of Administration, Disease Indication, Age Group, Distribution Channel, and Country/Sub-region)
- GCC (By Type)
- South Africa (By Type)
- Rest of the Middle East & Africa (By Type)
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
4. Key Insights
- 4.1. Pipeline Analysis, By Key Players
- 4.2. Technological Advancements in the Vaccines Market
- 4.3. Incidence/Prevalence of Disease Indications, 2025/2026
- 4.4. New Product Launches, By Key Players
- 4.5. Key Industry Developments - Mergers, Acquisitions, and Partnerships
- 4.6. Analysis: Biologics Trends in the Global Market
- 4.7. Impact of Tariff on the Vaccines Market
5. Global Vaccines Market Analysis, Insights and Forecast, 2021-2034
- 5.1. Market Analysis, Insights and Forecast - By Type
- 5.1.1. Recombinant/Conjugate/Subunit
- 5.1.2. Inactivated
- 5.1.3. Live Attenuated
- 5.1.4. Viral Vector
- 5.1.5. mRNA
- 5.1.6. Toxoid
- 5.1.7. Others
- 5.2. Market Analysis, Insights and Forecast - By Route of Administration
- 5.2.1. Parenteral
- 5.2.2. Oral
- 5.3. Market Analysis, Insights and Forecast - By Disease Indication
- 5.3.1. Viral Diseases
- 5.3.1.1. Hepatitis A
- 5.3.1.2. Hepatitis B
- 5.3.1.3. Influenza
- 5.3.1.4. Human Papillomavirus
- 5.3.1.5. Measles/Mumps/Rubella
- 5.3.1.6. Rotavirus
- 5.3.1.7. Herpes Zoster
- 5.3.1.8. Polio
- 5.3.1.9. RSV
- 5.3.1.10. Others
- 5.3.2. Bacterial Diseases
- 5.3.2.1. Meningococcal Disease
- 5.3.2.2. Pneumococcal Disease
- 5.3.2.3. Diphtheria/Tetanus/Pertussis
- 5.3.2.4. Others
- 5.3.3. Market Analysis, Insights and Forecast - By Age Group
- 5.3.3.1. Pediatric
- 5.3.3.2. Adolts
- 5.3.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 5.3.4.1. Hospital & Retail Pharmacies
- 5.3.4.2. Government Suppliers
- 5.3.4.3. Others
- 5.3.5. Market Analysis, Insights and Forecast - By Region
- 5.3.5.1. North America
- 5.3.5.2. Europe
- 5.3.5.3. Asia Pacific
- 5.3.5.4. Latin America
- 5.3.5.5. Middle East & Africa
- 5.3.1. Viral Diseases
6. North America Vaccines Market Analysis, Insights and Forecast, 2021-2034
- 6.1. Market Analysis, Insights and Forecast - By Type
- 6.1.1. Recombinant/Conjugate/Subunit
- 6.1.2. Inactivated
- 6.1.3. Live Attenuated
- 6.1.4. Viral Vector
- 6.1.5. mRNA
- 6.1.6. Toxoid
- 6.1.7. Others
- 6.2. Market Analysis, Insights and Forecast - By Route of Administration
- 6.2.1. Parenteral
- 6.2.2. Oral
- 6.3. Market Analysis, Insights and Forecast - By Disease Indication
- 6.3.1. Viral Diseases
- 6.3.1.1. Hepatitis A
- 6.3.1.2. Hepatitis B
- 6.3.1.3. Influenza
- 6.3.1.4. Human Papillomavirus
- 6.3.1.5. Measles/Mumps/Rubella
- 6.3.1.6. Rotavirus
- 6.3.1.7. Herpes Zoster
- 6.3.1.8. Polio
- 6.3.1.9. RSV
- 6.3.1.10. Others
- 6.3.2. Bacterial Diseases
- 6.3.2.1. Meningococcal Disease
- 6.3.2.2. Pneumococcal Disease
- 6.3.2.3. Diphtheria/Tetanus/Pertussis
- 6.3.2.4. Others
- 6.3.3. Market Analysis, Insights and Forecast - By Age Group
- 6.3.3.1. Pediatric
- 6.3.3.2. Adolts
- 6.3.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 6.3.4.1. Hospital & Retail Pharmacies
- 6.3.4.2. Government Suppliers
- 6.3.4.3. Others
- 6.3.5. Market Analysis, Insights and Forecast - By Country
- 6.3.5.1. U.S.
- 6.3.5.1.1. By Type
- 6.3.5.2. Canada
- 6.3.5.2.1. By Type
- 6.3.5.1. U.S.
- 6.3.1. Viral Diseases
7. Europe Vaccines Market Analysis, Insights and Forecast, 2021-2034
- 7.1. Market Analysis, Insights and Forecast - By Type
- 7.1.1. Recombinant/Conjugate/Subunit
- 7.1.2. Inactivated
- 7.1.3. Live Attenuated
- 7.1.4. Viral Vector
- 7.1.5. mRNA
- 7.1.6. Toxoid
- 7.1.7. Others
- 7.2. Market Analysis, Insights and Forecast - By Route of Administration
- 7.2.1. Parenteral
- 7.2.2. Oral
- 7.3. Market Analysis, Insights and Forecast - By Disease Indication
- 7.3.1. Viral Diseases
- 7.3.1.1. Hepatitis A
- 7.3.1.2. Hepatitis B
- 7.3.1.3. Influenza
- 7.3.1.4. Human Papillomavirus
- 7.3.1.5. Measles/Mumps/Rubella
- 7.3.1.6. Rotavirus
- 7.3.1.7. Herpes Zoster
- 7.3.1.8. Polio
- 7.3.1.9. RSV
- 7.3.1.10. Others
- 7.3.2. Bacterial Diseases
- 7.3.2.1. Meningococcal Disease
- 7.3.2.2. Pneumococcal Disease
- 7.3.2.3. Diphtheria/Tetanus/Pertussis
- 7.3.2.4. Others
- 7.3.3. Market Analysis, Insights and Forecast - By Age Group
- 7.3.3.1. Pediatric
- 7.3.3.2. Adolts
- 7.3.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 7.3.4.1. Hospital & Retail Pharmacies
- 7.3.4.2. Government Suppliers
- 7.3.4.3. Others
- 7.3.5. Market Analysis, Insights and Forecast - By Country/Sub-region
- 7.3.5.1. U.K.
- 7.3.5.1.1. By Type
- 7.3.5.2. Germany
- 7.3.5.2.1. By Type
- 7.3.5.3. France
- 7.3.5.3.1. By Type
- 7.3.5.4. Spain
- 7.3.5.4.1. By Type
- 7.3.5.5. Italy
- 7.3.5.5.1. By Type
- 7.3.5.6. Scandinavia
- 7.3.5.6.1. By Type
- 7.3.5.7. Rest of Europe
- 7.3.5.7.1. By Type
- 7.3.5.1. U.K.
- 7.3.1. Viral Diseases
8. Asia Pacific Vaccines Market Analysis, Insights and Forecast, 2021-2034
- 8.1. Market Analysis, Insights and Forecast - By Type
- 8.1.1. Recombinant/Conjugate/Subunit
- 8.1.2. Inactivated
- 8.1.3. Live Attenuated
- 8.1.4. Viral Vector
- 8.1.5. mRNA
- 8.1.6. Toxoid
- 8.1.7. Others
- 8.2. Market Analysis, Insights and Forecast - By Route of Administration
- 8.2.1. Parenteral
- 8.2.2. Oral
- 8.3. Market Analysis, Insights and Forecast - By Disease Indication
- 8.3.1. Viral Diseases
- 8.3.1.1. Hepatitis A
- 8.3.1.2. Hepatitis B
- 8.3.1.3. Influenza
- 8.3.1.4. Human Papillomavirus
- 8.3.1.5. Measles/Mumps/Rubella
- 8.3.1.6. Rotavirus
- 8.3.1.7. Herpes Zoster
- 8.3.1.8. Polio
- 8.3.1.9. RSV
- 8.3.1.10. Others
- 8.3.2. Bacterial Diseases
- 8.3.2.1. Meningococcal Disease
- 8.3.2.2. Pneumococcal Disease
- 8.3.2.3. Diphtheria/Tetanus/Pertussis
- 8.3.2.4. Others
- 8.3.3. Market Analysis, Insights and Forecast - By Age Group
- 8.3.3.1. Pediatric
- 8.3.3.2. Adolts
- 8.3.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 8.3.4.1. Hospital & Retail Pharmacies
- 8.3.4.2. Government Suppliers
- 8.3.4.3. Others
- 8.3.5. Market Analysis, Insights and Forecast - By Country/Sub-region
- 8.3.5.1. Japan
- 8.3.5.1.1. By Type
- 8.3.5.2. China
- 8.3.5.2.1. By Type
- 8.3.5.3. India
- 8.3.5.3.1. By Type
- 8.3.5.4. Australia
- 8.3.5.4.1. By Type
- 8.3.5.5. Southeast Asia
- 8.3.5.5.1. By Type
- 8.3.5.6. Rest of Asia Pacific
- 8.3.5.6.1. By Type
- 8.3.5.1. Japan
- 8.3.1. Viral Diseases
9. Latin America Vaccines Market Analysis, Insights and Forecast, 2021-2034
- 9.1. Market Analysis, Insights and Forecast - By Type
- 9.1.1. Recombinant/Conjugate/Subunit
- 9.1.2. Inactivated
- 9.1.3. Live Attenuated
- 9.1.4. Viral Vector
- 9.1.5. mRNA
- 9.1.6. Toxoid
- 9.1.7. Others
- 9.2. Market Analysis, Insights and Forecast - By Route of Administration
- 9.2.1. Parenteral
- 9.2.2. Oral
- 9.3. Market Analysis, Insights and Forecast - By Disease Indication
- 9.3.1. Viral Diseases
- 9.3.1.1. Hepatitis A
- 9.3.1.2. Hepatitis B
- 9.3.1.3. Influenza
- 9.3.1.4. Human Papillomavirus
- 9.3.1.5. Measles/Mumps/Rubella
- 9.3.1.6. Rotavirus
- 9.3.1.7. Herpes Zoster
- 9.3.1.8. Polio
- 9.3.1.9. RSV
- 9.3.1.10. Others
- 9.3.2. Bacterial Diseases
- 9.3.2.1. Meningococcal Disease
- 9.3.2.2. Pneumococcal Disease
- 9.3.2.3. Diphtheria/Tetanus/Pertussis
- 9.3.2.4. Others
- 9.3.3. Market Analysis, Insights and Forecast - By Age Group
- 9.3.3.1. Pediatric
- 9.3.3.2. Adolts
- 9.3.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 9.3.4.1. Hospital & Retail Pharmacies
- 9.3.4.2. Government Suppliers
- 9.3.4.3. Others
- 9.3.5. Market Analysis, Insights and Forecast - By Country/Sub-region
- 9.3.5.1. Brazil
- 9.3.5.1.1. By Type
- 9.3.5.2. Mexico
- 9.3.5.2.1. By Type
- 9.3.5.3. Rest of Latin America
- 9.3.5.3.1. By Type
- 9.3.5.1. Brazil
- 9.3.1. Viral Diseases
10. Middle East & Africa Vaccines Market Analysis, Insights and Forecast, 2021-2034
- 10.1. Market Analysis, Insights and Forecast - By Type
- 10.1.1. Recombinant/Conjugate/Subunit
- 10.1.2. Inactivated
- 10.1.3. Live Attenuated
- 10.1.4. Viral Vector
- 10.1.5. mRNA
- 10.1.6. Toxoid
- 10.1.7. Others
- 10.2. Market Analysis, Insights and Forecast - By Route of Administration
- 10.2.1. Parenteral
- 10.2.2. Oral
- 10.3. Market Analysis, Insights and Forecast - By Disease Indication
- 10.3.1. Viral Diseases
- 10.3.1.1. Hepatitis A
- 10.3.1.2. Hepatitis B
- 10.3.1.3. Influenza
- 10.3.1.4. Human Papillomavirus
- 10.3.1.5. Measles/Mumps/Rubella
- 10.3.1.6. Rotavirus
- 10.3.1.7. Herpes Zoster
- 10.3.1.8. Polio
- 10.3.1.9. RSV
- 10.3.1.10. Others
- 10.3.2. Bacterial Diseases
- 10.3.2.1. Meningococcal Disease
- 10.3.2.2. Pneumococcal Disease
- 10.3.2.3. Diphtheria/Tetanus/Pertussis
- 10.3.2.4. Others
- 10.3.3. Market Analysis, Insights and Forecast - By Age Group
- 10.3.3.1. Pediatric
- 10.3.3.2. Adolts
- 10.3.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 10.3.4.1. Hospital & Retail Pharmacies
- 10.3.4.2. Government Suppliers
- 10.3.4.3. Others
- 10.3.5. Market Analysis, Insights and Forecast - By Country/Sub-region
- 10.3.5.1. GCC Countries
- 10.3.5.1.1. By Type
- 10.3.5.2. South Africa
- 10.3.5.2.1. By Type
- 10.3.5.3. Rest of Middle East & Africa
- 10.3.5.3.1. By Type
- 10.3.5.1. GCC Countries
- 10.3.1. Viral Diseases
11. Competitive Analysis
- 11.1. Global Market Share Analysis (2025)
- 11.2. Company Profiles
- 11.2.1. Pfizer Inc.
- 11.2.1.1. Overview
- 11.2.1.2. Products
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Strategies
- 11.2.1.6. Financials (Based on Availability)
- 11.2.2. Sanofi
- 11.2.2.1. Overview
- 11.2.2.2. Products
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Strategies
- 11.2.2.6. Financials (Based on Availability)
- 11.2.3. CSL
- 11.2.3.1. Overview
- 11.2.3.2. Products
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Strategies
- 11.2.3.6. Financials (Based on Availability)
- 11.2.4. AstraZeneca
- 11.2.4.1. Overview
- 11.2.4.2. Products
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Strategies
- 11.2.4.6. Financials (Based on Availability)
- 11.2.5. Bavarian Nordic
- 11.2.5.1. Overview
- 11.2.5.2. Products
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Strategies
- 11.2.5.6. Financials (Based on Availability)
- 11.2.6. GSK plc.
- 11.2.6.1. Overview
- 11.2.6.2. Products
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Strategies
- 11.2.6.6. Financials (Based on Availability)
- 11.2.7. EMERGENT
- 11.2.7.1. Overview
- 11.2.7.2. Products
- 11.2.7.3. SWOT Analysis
- 11.2.7.4. Recent Developments
- 11.2.7.5. Strategies
- 11.2.7.6. Financials (Based on Availability)
- 11.2.8. Merck & Co., Inc.
- 11.2.8.1. Overview
- 11.2.8.2. Products
- 11.2.8.3. SWOT Analysis
- 11.2.8.4. Recent Developments
- 11.2.8.5. Strategies
- 11.2.8.6. Financials (Based on Availability)
- 11.2.9. Inovio Pharmaceuticals, Inc.
- 11.2.9.1. Overview
- 11.2.9.2. Products
- 11.2.9.3. SWOT Analysis
- 11.2.9.4. Recent Developments
- 11.2.9.5. Strategies
- 11.2.9.6. Financials (Based on Availability)
- 11.2.1. Pfizer Inc.
List of Tables
- Table 1: Global Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 2: Global Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 3: Global Vaccines Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
- Table 4: Global Vaccines Market Revenue (USD billion) Forecast, by Viral Diseases, 2021-2034
- Table 5: Global Vaccines Market Revenue (USD billion) Forecast, by Bacterial Diseases, 2021-2034
- Table 6: Global Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
- Table 7: Global Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 8: Global Vaccines Market Revenue (USD billion) Forecast, by Region, 2021-2034
- Table 10: North America Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 11: North America Vaccines Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
- Table 12: North America Vaccines Market Revenue (USD billion) Forecast, by Viral Diseases, 2021-2034
- Table 13: North America Vaccines Market Revenue (USD billion) Forecast, by Bacterial Diseases, 2021-2034
- Table 14: North America Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
- Table 15: North America Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 16: North America Vaccines Market Revenue (USD billion) Forecast, By Country, 2021-2034
- Table 17: U.S. Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 18: Canada Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 19: Europe Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 20: Europe Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 21: Europe Vaccines Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
- Table 22: Europe Vaccines Market Revenue (USD billion) Forecast, by Viral Diseases, 2021-2034
- Table 23: Europe Vaccines Market Revenue (USD billion) Forecast, by Bacterial Diseases, 2021-2034
- Table 24: Europe Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
- Table 25: Europe Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 26: Europe Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 27: Germany Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 28: France Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 29: U.K. Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 30: Italy Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 31: Spain Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 32: Scandinavia Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 33: Rest of Europe Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 34: Asia Pacific Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 35: Asia Pacific Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 36: Asia Pacific Vaccines Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
- Table 37: Asia Pacific Vaccines Market Revenue (USD billion) Forecast, by Viral Diseases, 2021-2034
- Table 38: Asia Pacific Vaccines Market Revenue (USD billion) Forecast, by Bacterial Diseases, 2021-2034
- Table 39: Asia Pacific Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
- Table 40: Asia Pacific Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 41: Asia Pacific Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 42: India Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 43: China Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 44: Japan Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 45: Australia Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 46: South East Asia Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 47: Rest of Asia Pacific Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 48: Latin America Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 49: Latin America Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 50: Latin America Vaccines Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
- Table 51: Latin America Vaccines Market Revenue (USD billion) Forecast, by Viral Diseases, 2021-2034
- Table 52: Latin America Vaccines Market Revenue (USD billion) Forecast, by Bacterial Diseases, 2021-2034
- Table 53: Latin America Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
- Table 54: Latin America Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 55: Latin America Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 56: Brazil Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 57: Mexico Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 58: Rest of Latin America Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 59: Middle East & Africa Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 60: Middle East & Africa Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 61: Middle East & Africa Vaccines Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
- Table 62: Middle East & Africa Vaccines Market Revenue (USD billion) Forecast, by Viral Diseases, 2021-2034
- Table 63: Middle East & Africa Vaccines Market Revenue (USD billion) Forecast, by Bacterial Diseases, 2021-2034
- Table 64: Middle East & Africa Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
- Table 65: Middle East & Africa Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 66: Middle East & Africa Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 67: GCC Countries Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 68: South Africa Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 69: Rest of Middle East & Africa Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
List of Figures
- Figure 1: Global Vaccines Market Revenue Breakdown (USD billion, %) by Region, 2026 & 2034
- Figure 2: Global Vaccines Market Value Share (%), by Type, 2026 & 2034
- Figure 3: Global Vaccines Market Value Share (%), by Route of Administration, 2026 & 2034
- Figure 4: Global Vaccines Market Value Share (%), by Disease Indication, 2026 & 2034
- Figure 5: Global Vaccines Market Value Share (%), by Age Group, 2026 & 2034
- Figure 6: Global Vaccines Market Value Share (%), by Distribution Channel, 2026 & 2034
- Figure 7: Global Vaccines Market Value (USD billion), by Region, 2026 & 2034
- Figure 8: North America Vaccines Market Value (USD billion), by Type, 2026 & 2034
- Figure 9: North America Vaccines Market Value Share (%), by Type, 2025
- Figure 10: North America Vaccines Market Value (USD billion), by Route of Administration, 2026 & 2034
- Figure 11: North America Vaccines Market Value Share (%), by Route of Administration, 2025
- Figure 12: North America Vaccines Market Value (USD billion), by Disease Indication, 2026 & 2034
- Figure 13: North America Vaccines Market Value Share (%), by Disease Indication, 2025
- Figure 14: North America Vaccines Market Value (USD billion), by Age Group, 2026 & 2034
- Figure 15: North America Vaccines Market Value Share (%), by Age Group, 2025
- Figure 16: North America Vaccines Market Value (USD billion), by Distribution Channel, 2026 & 2034
- Figure 17: North America Vaccines Market Value Share (%), by Distribution Channel, 2025
- Figure 18: North America Vaccines Market Value (USD billion), By Country, 2026 & 2034
- Figure 19: North America Vaccines Market Value Share (%), By Country, 2025
- Figure 20: Europe Vaccines Market Value (USD billion), by Type, 2026 & 2034
- Figure 21: Europe Vaccines Market Value Share (%), by Type, 2025
- Figure 22: Europe Vaccines Market Value (USD billion), by Route of Administration, 2026 & 2034
- Figure 23: Europe Vaccines Market Value Share (%), by Route of Administration, 2025
- Figure 24: Europe Vaccines Market Value (USD billion), by Disease Indication, 2026 & 2034
- Figure 25: Europe Vaccines Market Value Share (%), by Disease Indication, 2025
- Figure 26: Europe Vaccines Market Value (USD billion), by Age Group, 2026 & 2034
- Figure 27: Europe Vaccines Market Value Share (%), by Age Group, 2025
- Figure 28: Europe Vaccines Market Value (USD billion), by Distribution Channel, 2026 & 2034
- Figure 29: Europe Vaccines Market Value Share (%), by Distribution Channel, 2025
- Figure 30: Europe Vaccines Market Value (USD billion), By Country/ Sub-region, 2026 & 2034
- Figure 31: Europe Vaccines Market Value Share (%), By Country/ Sub-region, 2025
- Figure 32: Asia Pacific Vaccines Market Value (USD billion), by Type, 2026 & 2034
- Figure 33: Asia Pacific Vaccines Market Value Share (%), by Type, 2025
- Figure 34: Asia Pacific Vaccines Market Value (USD billion), by Route of Administration, 2026 & 2034
- Figure 35: Asia Pacific Vaccines Market Value Share (%), by Route of Administration, 2025
- Figure 36: Asia Pacific Vaccines Market Value (USD billion), by Disease Indication, 2026 & 2034
- Figure 37: Asia Pacific Vaccines Market Value Share (%), by Disease Indication, 2025
- Figure 38: Asia Pacific Vaccines Market Value (USD billion), by Age Group, 2026 & 2034
- Figure 39: Asia Pacific Vaccines Market Value Share (%), by Age Group, 2025
- Figure 40: Asia Pacific Vaccines Market Value (USD billion), by Distribution Channel, 2026 & 2034
- Figure 41: Asia Pacific Vaccines Market Value Share (%), by Distribution Channel, 2025
- Figure 42: Asia Pacific Vaccines Market Value (USD billion), By Country/ Sub-region, 2026 & 2034
- Figure 43: Asia Pacific Vaccines Market Value Share (%), By Country/ Sub-region, 2025
- Figure 44: Latin America Vaccines Market Value (USD billion), by Type, 2026 & 2034
- Figure 45: Latin America Vaccines Market Value Share (%), by Type, 2025
- Figure 46: Latin America Vaccines Market Value (USD billion), by Route of Administration, 2026 & 2034
- Figure 47: Latin America Vaccines Market Value Share (%), by Route of Administration, 2025
- Figure 48: Latin America Vaccines Market Value (USD billion), by Disease Indication, 2026 & 2034
- Figure 49: Latin America Vaccines Market Value Share (%), by Disease Indication, 2025
- Figure 50: Latin America Vaccines Market Value (USD billion), by Age Group, 2026 & 2034
- Figure 51: Latin America Vaccines Market Value Share (%), by Age Group, 2025
- Figure 52: Latin America Vaccines Market Value (USD billion), by Distribution Channel, 2026 & 2034
- Figure 53: Latin America Vaccines Market Value Share (%), by Distribution Channel, 2025
- Figure 54: Latin America Vaccines Market Value (USD billion), By Country/ Sub-region, 2026 & 2034
- Figure 55: Latin America Vaccines Market Value Share (%), By Country/ Sub-region, 2025
- Figure 56: Middle East & Africa Vaccines Market Value (USD billion), by Type, 2026 & 2034
- Figure 57: Middle East & Africa Vaccines Market Value Share (%), by Type, 2025
- Figure 58: Middle East & Africa Vaccines Market Value (USD billion), by Route of Administration, 2026 & 2034
- Figure 59: Middle East & Africa Vaccines Market Value Share (%), by Route of Administration, 2025
- Figure 60: Middle East & Africa Vaccines Market Value (USD billion), by Disease Indication, 2026 & 2034
- Figure 61: Middle East & Africa Vaccines Market Value Share (%), by Disease Indication, 2025
- Figure 62: Middle East & Africa Vaccines Market Value (USD billion), by Age Group, 2026 & 2034
- Figure 63: Middle East & Africa Vaccines Market Value Share (%), by Age Group, 2025
- Figure 64: Middle East & Africa Vaccines Market Value (USD billion), by Distribution Channel, 2026 & 2034
- Figure 65: Middle East & Africa Vaccines Market Value Share (%), by Distribution Channel, 2025
- Figure 66: Middle East & Africa Vaccines Market Value (USD billion), By Country/ Sub-region, 2026 & 2034
- Figure 67: Middle East & Africa Vaccines Market Value Share (%), By Country/ Sub-region, 2025
- Figure 68: Global Vaccines Market Share (%), By Company, 2025
